PRESS RELEASE

AgenT Announces Initiation of Its APOLLO Study, a Retrospective and Multi-Center Study to Validate the First Blood-based Diagnosis of the Silent Phase of Alzheimer's Disease

September 21, 2021 2:00 PM Central European Time

PARIS, France – AgenT, a life sciences company whose mission is to defeat Alzheimer's by targeting the silent phase, announces the launch of its first clinical validation study for its Alzheimer's multiomics blood test.

Alzheimer's is an extremely complex disease and to find the right pattern among billions of potential signals would have required thousands of well-annotated human blood samples. Instead, AgenT pre-identified using artificial intelligence the most informative biomarkers on the first animal model of the silent phase of Alzheimer's[1]. Then, the team confirmed these diagnostic biomarkers on 232 human plasma samples sampled up to 15 years before dementia[2]. After this successful clinical proof-of-concept, AgenT aims to improve the generalizability of its patented blood biomarkers and the associated neural network during its APOLLO clinical validation study.

APOLLO is a multi-center study to evaluate AgenT's blood test performance on retrospective plasma samples. The first phase of this study involves 750 plasma samples (8 independent cohorts) from international research institutes in the US, Europe and Australia[3]. The control group consists of healthy individuals, without cognitive impairment, and other dementias excluding Alzheimer's. The Alzheimer's group consists of patients sampled in asymptomatic, prodromal and dementia phases. Patients have been followed up to 18 years until their conversion to dementia.

"Alzheimer's is a progressive disease that begins 20 years or more before symptoms arise. Considering the urgent need for an early and accurate blood diagnosis of the disease, the use of retrospective plasma samples is the best way to validate our diagnostic test without waiting many years." said Jérôme Braudeau, PhD, Co-Founder and CEO of AgenT. "We particularly

thank the leading research institutes and their clinicians that trusted us by giving us access to these extremely valuable samples for the validation of our test. Alzheimer's is a global pandemic, and we need this type of international collaboration to defeat this disease." enthused Jérôme Braudeau.

AgenT's patented biomarkers are currently being quantified using targeted mass spectrometry in the 750 plasma samples collected up to 18 years before dementia. The final results of the clinical validation are expected in March 2022.

With new Alzheimer's treatments coming to market, there is an urgent need for a simple blood test that detects the disease before the onset of cognitive impairment. In a study published last year, researchers predicted that an accurate Alzheimer's blood test would reduce wait times from 45 months to about 10 months for getting an Alzheimer's treatment in the US[4].
"Developing a simple and accurate blood test that diagnoses Alzheimer's from the asymptomatic stage is a huge opportunity for health systems to reduce the burden of the disease for the patients and their families and shift the paradigm to healthy ageing." said Baptiste Billoir, Co-Founder and CFO of AgenT.

If positive results are confirmed during this clinical validation, AgenT's blood test would be the first to detect Alzheimer's from the asymptomatic stage with a high level of accuracy.

(1) *βAPP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Mode of Alzheimer's Disease, Audrain et al., 2018*
(2) *Blood-based Detection of Early-stage Alzheimer's Using Multiomics and Machine Learning, AAIC 2020*
(3) *Research partners involved:*
   - **USA:** *Stanford (Pr. Tony Wyss-Coray), Washington University in St Louis (Pr. Krista Moulder), Banner Alzheimer's Institute (Dr. Eric Reiman), University of Washington (Dr. Suman Jaydev)*
   - **Spain:** *Sant Pau Hospital - Neurology & Down Syndrome Units (Dr. Alberto Lleo and Dr. Juan Fortea)*
   - **France:** *Lariboisière Hospital (Pr. Claire Paquet)*
   - **Australia:** *Florey's University (Pr. Colin Masters)*
(4) *Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times, Mattke et al., 2020*

About AgenT

AgenT is a life sciences company whose mission is to defeat Alzheimer's by targeting the silent phase. By combining multi-omics assays with advanced machine learning techniques, they found new blood biomarkers deregulated from the earliest stages of the disease. Using this proprietary database, they are developing an accurate blood diagnosis and the next generation of precision therapies to treat Alzheimer's. Agent is headquartered in Paris, France.

For more information about AgenT, please visit www.agent-biotech.com.

Contact:

Jérôme Braudeau

Jerome.braudeau@agent-biotech.com

+33 6 11 10 26 95